Clinical trials: Clopidogrel
Noncardioembolic Cerebral Infarction
Cilostazol Stroke Prevention Study for Antiplatelet Combination
To examine the efficacy and safety of dual antiplatelet therapy (DAPT) including cilostazol (Pletaal OD Tablet ®) in comparison with antiplatelet monotherapy (excluding cilostazol) for secondary prevention of ischemic stroke in…
- Trial name
- CSPS・com (NCT01995370)
- Testing
- aspirin, clopidogrel, cilostazol
- Where
- Japan
- Volunteers
- 1,884 people
- Sponsor
- Japan Cardiovascular Research Foundation
Diabetes Mellitus Type II, Acute Coronary Syndrome
VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel
The purpose of this study is to determine if, in type 2 diabetic patients undergoing treatment with PCI and a stent, who fail to respond to normal doses of clopidogrel, a loading dose of 60 mg of prasugrel followed by 10 mg once…
- Trial name
- VERDI (NCT01684813)
- Testing
- Prasugrel., Clopidogrel
- Where
- Spain
- Volunteers
- 65 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Coronary Artery Disease
Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan
The purpose of this study is to evaluate the effect of high dose clopidogrel as the antiplatelet therapy on inhibition of platelet aggregation in Japanese patients scheduled for percutaneous coronary intervention due to ischemic…
- Trial name
- CHOICE (NCT01069302)
- Testing
- Clopidogrel
- Where
- Japan
- Volunteers
- 106 people
- Sponsor
- Takeshi Morimoto
Coronary Artery Disease
Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving Antiplatelet Therapy With Clopidogrel (Plavix)
Clopidogrel (Plavix), a platelet ADP receptor antagonist, has become the standard of care to prevent thrombosis in interventional cardiology and is increasingly being used in unstable angina and NSTEMI.
- Trial name
- NCT00257751
- Testing
- Aprotinine
- Volunteers
- 400 people
- Sponsor
- Oslo University Hospital
Acute Coronary Syndrome, Chronic Kidney Disease
Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients
A 4 week-duration cross-over study on Ticagrelor and Clopidogrel for the Acute Coronary Syndrome (ACS) and Chronic Kidney Disease (CKD) subjects, focusing on the platelet inhibition and safety observation.
- Conditions
- Acute Coronary Syndrome, Chronic Kidney Disease, End-Stage Renal Disease
- Trial name
- APROVE-CKD (NCT02459288)
- Testing
- Clopidogrel first, Ticagrelor first
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Ping-Yen Liu
Coronary Artery Disease
Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination-2nd Trial
The purpose of this study is to compare pharmacokinetics between fixed-dose combination and separate combination of clopidogrel 75mg/aspirin 100mg.
- Trial name
- NCT01496261
- Testing
- Clopidogrel and Aspirin, Fixed dose combination of clopidogrel/aspirin
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Cardiovascular Disease, Acute Coronary Syndrome
Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence
Percutaneous coronary intervention (PCI) is a common invasive cardiovascular procedure performed in the VA with over 13,000 procedures in FY10.
- Trial name
- NCT01609842
- Testing
- Multifaceted Intervention with pharmacist and IVR
- Where
- 15 sites in United States
- Volunteers
- 14,573 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Myocardial Infarction
Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)
Although the optimal duration of clopidogrel (an anti-platelet agent) therapy has been established after bare metal stent implantation in the blood vessels of the heart, there is lack of consensus regarding the optimal duration…
- Trial name
- SCORE (NCT00781573)
- Testing
- Clopidogrel
- Where
- 3 sites in United States, Greece and 1 more
- Volunteers
- 167 people
- Sponsor
- North Texas Veterans Healthcare System
Osteoarthritis of the Knee, Coagulopathy
Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants
The purpose of this study is to see if using a topical nonsteroidal antiinflammatory drug (Pennsaid) to treat osteoarthritis knee pain will affect coagulation values in patients who are also taking anticoagulant or antithrombotic…
- Trial name
- ATCCTCP-1 (NCT01511939)
- Testing
- Pennsaid
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Nathan Wei, MD, FACP, FACR:
Acute Coronary Syndrome, Acute Myocardial Infarction
Influence of Esomeprazole on Antiplatelet Action of Clopidogrel Associated With Aspirin
The investigators examine the influence of esomeprazole versus famotidine on antiplatelet action of clopidogrel associated with aspirin.
- Trial name
- NCT01062516
- Testing
- esomeprazole 20 mg daily, famotidine 40 mg daily
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ruttonjee Hospital
Cardiovascular Disease
Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study
The primary objective of this trial is to demonstrate the non-inferiority of clopidogrel compared to prasugrel over 6 months in cardiovascular disease patients when the clopidogrel cohort is limited to the estimated 70% of the…
- Trial name
- GeCCO (NCT00995514)
- Where
- United States
- Volunteers
- 4,471 people
- Sponsor
- Medco Health Solutions, Inc.
Diabetes Type 2, Diabetic Nephropathy
Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy
The purpose of this study is to determine whether the combination with ramipril and clopidogrel leads to further improvement of endothelial function, reduction of oxidative stress and reduction of vascular inflammation, compared…
- Conditions
- Diabetes Type 2, Diabetic Nephropathy, Vascular Disease
- Trial name
- NCT01743014
- Testing
- Ramipril, Clopidogrel
- Where
- 2 sites in Greece
- Volunteers
- 60 people
- Sponsor
- AHEPA University Hospital
Myocardial Infarction, ST Segment Elevation Myocardial Infarction (STEMI)
A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study
This is a prospective randomized study, which investigates the coronary microvascular function as assessed by coronary angiography after administration of ticagrelor compared with clopidogrel in patients with myocardial…
- Trial name
- MIRTOS (NCT02429271)
- Testing
- Ticagrelor, Clopidogrel, Percutaneous Coronary Intervention (PCI)
- Where
- Greece
- Volunteers
- 336 people
- Sponsor
- Hellenic Cardiovascular Research Society
Acute Coronary Syndrome:, Non ST Elevation Myocardial Infarction
Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel
The administration of these drugs is realized according to the European Society of Cardiology guidelines. All patients will be pretreated with aspirin 300 mg orally, heparin iv to maintain an activated clotting time of >250 sec…
- Conditions
- Acute Coronary Syndrome:, Non ST Elevation Myocardial Infarction, ST Elevation Myocardial Infarction, Unstable Angina
- Trial name
- NCT02032290
- Testing
- Assessment of Coronary Flow Reserve, Percutaneous coronary intervention, ticagrelor loading
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- Azienda Policlinico Umberto I
Peripheral Arterial Disease (PAD), Amputation
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore…
- Conditions
- Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis)
- Trial name
- NCT07613840
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 484 people
- Sponsor
- Massachusetts General Hospital
Coronary Artery Disease
Clopidogrel Proton-Pump Inhibitors Study
To find out the impact of two different proton-pump inhibitors (PPIs) (Omeprazole and Pantoprazole) on platelet function in patients with stable coronary artery disease (CAD) on clopidogrel therapy.
- Trial name
- NCT01016717
- Testing
- Omeprazole, Pantoprazole
- Where
- Israel
- Sponsor
- Sheba Medical Center
Healthy
Influence of Clopidogrel on the Pharmacodynamics and Safety of Fradafiban in Healthy Male Subjects
To assess the influence of 75 mg Clopidogrel on the pharmacodynamics and safety of 30 mg Lefradafiban tid
- Trial name
- NCT02265289
- Testing
- Lefradafiban, Clopidogrel
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Bioequivalence Study Comparing Clopidogrel/Aspirin Combination Tablet With Coadministration of Clopidogrel and Aspirin
The purpose of this study is to evaluate pharmacokinetics and safety after oral administration of clopidogrel and aspirin in free combination as HCP0911.
- Trial name
- NCT01448330
- Testing
- HCP0911 / clopidogrel, aspirin
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Smoking Status, Genetic Risk Factors
Effect of Smoking Status and Genetic Risk Factors on Restenosis and Efficacy of Clopidogrel After de Novo Percutaneous Coronary Intervention
Restenosis occurs for many different reasons. Over the years, many predictive clinical, biological, genetic, epigenetic, lesion-related, and procedural risk factors for restenosis have been identified.
- Conditions
- Smoking Status, Genetic Risk Factors, Restenosis, Clopidogrel
- Trial name
- NCT03613337
- Testing
- clinical restenosis
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Cui Yimin
Ischemic Stroke
Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke
Along with the current clinical trial, the efficacy and safety of a 300 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel ischemic stroke compared to 200 mg cilostazol were assessed through…
- Trial name
- NCT06242145
- Testing
- Clopidogrel tablet, Cilostazol 100 MG
- Where
- Egypt
- Volunteers
- 580 people
- Sponsor
- Kafrelsheikh University